Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
| Autor: | Jau Ching Wu, Tsung Hsi Tu, Chin Chu Ko, Hsueh Chen Huang, Wen Cheng Huang, Henrich Cheng, Shih Fong Huang, Y. Tsai |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Adult Male Adolescent Science Article 03 medical and health sciences Young Adult 0302 clinical medicine Lumbar Medicine Humans Prospective Studies Young adult Prospective cohort study Adverse effect Spinal cord injury Neurolysis Spinal Cord Injuries Aged Multidisciplinary business.industry Recovery of Function Middle Aged medicine.disease Spinal cord Nerve Regeneration Clinical trial 030104 developmental biology medicine.anatomical_structure Anesthesia Chronic Disease Fibroblast Growth Factor 1 Female business 030217 neurology & neurosurgery |
| Zdroj: | Scientific Reports Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018) |
| ISSN: | 2045-2322 |
| Popis: | Few treatments have proven effective for patients with chronic spinal cord injury (SCI). This study aimed to evaluate the efficacy and safety of acidic fibroblast growth factor (aFGF) in human SCI. This was an open-label prospective clinical trial of aFGF with an extended follow-up to 48 months. All patients were treated with aFGF 3 times, including once directly applied to the injured spinal cord during neurolysis surgery, and twice via lumbar punctures at 3- and 6-months post-operation. Every patient was evaluated with standardized measurements of neurological functions. The trial initially enrolled 60 patients (30 cervical and 30 thoracolumbar SCI), but only 46 (21 cervical- and 25 thoracolumbar-SCI) completed the follow-up. The ASIA impairment scales, motor, pin prick, light touch, and FIM motor subtotal scores were all improved in both groups, except that the ASIA scores of light touch only demonstrated tendency of increase in the cervical-SCI group. All patients had a decrease in dependence, and there were no major adverse events or other oncological problems throughout the follow-up. At 48 months, the study demonstrated that aFGF was safe, feasible, and could yield modest functional improvement in chronic SCI patients. Further randomized control investigations are warranted for validation of its optimal dosage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|